FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.
What happened
FDA inspected the Aspen Biopharma Labs drug manufacturing facility in Hyderabad, India, from September 16 to September 21, 2024. FDA found the facility in disrepair, with manufacturing areas open to the outdoors and inadequate separation for high-potency or toxic drugs, plus incomplete process validation, inadequate cleaning validation, data-integrity problems, and an inadequate stability program. The company later recalled all U.S.-distributed drugs, and FDA placed its drugs on Import Alert 66-40.
What FDA found
FDA found the facility in disrepair, with manufacturing areas open to the outdoors and inadequate separation for high-potency or toxic drugs, including drugs made in a common area.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)FDA said commercial-size process validation was not completed, and the company relied on development-size lots made with different equipment.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)FDA found no adequate cleaning validation, and investigators saw equipment labeled 'Cleaned' with liquid and residue on product-contact surfaces.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company admitted to backdating a quality-control lab document and signed a declaration that commercial drugs shipped to the U.S. were not supported by appropriate original data.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)FDA said the stability program was inadequate and lacked data to support the retest date for drugs shipped to the United States.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells the company to respond in writing within 15 working days with what it has done to correct the deviations and prevent recurrence, and to clarify whether it will stop making drugs for the U.S. market and notify FDA before resuming. If it cannot finish corrective actions in that time, it must state why and give a completion schedule.
Who should pay attention
- U.S. drugmakers and repackagers that buy APIs from Indian manufacturers
- companies with Aspen APIs or finished drugs in their supply chain
- quality teams tracking supplier qualification and import alerts
This is a summary. Read the original letter on fda.gov.